About ACS
ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.
TechNavio's analysts forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.
Covered in this Report
The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.
TechNavio's report, the Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Astra Zeneca
• BMS
• Eli Lilly
• GSK
• Sanofi
Other Prominent Vendors
• AbbVie
• Amgen
• Bayer
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Portola Pharmaceuticals
• Teva Pharmaceutical
Market Driver
• Increase in Aging Population
• For a full, detailed list, view our report
Market Challenge
• Multiple Patent Expirations
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Burden of Disease
06.3 Etiology
06.4 Pathophysiology
06.4.1 Myocardial Dysfunction
06.4.2 MI
06.4.3 Electrical Dysfunction
06.5 Prognosis
06.6 Epidemiology
06.6.1 Prevalence of Coronary Artery Disease
06.7 Diagnosis
06.7.1 ECG
06.7.2 Blood Tests
06.7.3 Nuclear Scan
06.7.4 CT
06.8 Management
07. ACS Pipeline Landscape
07.1 Key Pipeline Molecules
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by ECG Output
10 Geographical Segmentation
11 Buying Criteria
12 Market Growth Drivers
13 Drivers and their Impact
14 Market Challenges
15 Impact of Drivers and Challenges
16 Market Trends
17 Trends and their Impact
18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 AstraZeneca
18.2.2 Bristol-Myers Squibb
18.2.3 Eli Lilly
18.2.4 GlaxoSmithKline
18.2.5 Sanofi
18.3 Other Prominent Vendors
19 Key Vendor Analysis
19.1 AstraZeneca
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2011-2013
19.1.5 Revenue by Geography
19.1.6 Business Strategy
19.1.7 Key Developments
19.1.8 SWOT Analysis
19.2 Bristol-Myers Squibb
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Revenue by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Eli Lilly
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue
19.3.4 Revenue by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 GlaxoSmithKline
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Revenue by Geography
19.4.6 Pipeline Products
19.4.7 Business Strategy
19.4.8 Key Information
19.4.9 SWOT Analysis
19.5 Sanofi
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Revenue by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20 Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Spectrum of ACS
Exhibit 3: Overview of ACS
Exhibit 4: Pathogenesis of ACS
Exhibit 5: Hospitalized Incident Cases of ACS 2014-2019 (millions)
Exhibit 6: Epidemiologic Transition of CV Diseases
Exhibit 7: Initial Drug Therapy for ACS
Exhibit 8: Adjunctive Drug Therapy for ACS
Exhibit 9: Surgery and Other Procedures
Exhibit 10: Snapshot of Global ACS Market 2014
Exhibit 11: Global ACS Market 2014-2019 (US$ billion)
Exhibit 12: Global ACS Market Share of Branded and Generic Drugs 2014 and 2019 (in Percent)
Exhibit 13: Segmentation of Global ACS Market by ECG Output
Exhibit 14: Diagrammatic Representation of STEMI, NSTEMI, and UA
Exhibit 15: Segmentation of Global ACS Market by ECG Output 2014
Exhibit 16: Global ACS Market by Geography 2014
Exhibit 17: Drivers of Global ACS Market
Exhibit 18: Comparison of Elderly Population 2012 and 2050 (Aged 65 and Older)
Exhibit 19: Challenges in Global ACS Market
Exhibit 20: Trends in Global ACS Market
Exhibit 21: Global Revenue of AstraZeneca for CV and Metabolic Diseases 2011-2013 (US$ million)
Exhibit 22: Estimated Filings of Brilinta/Brilique
Exhibit 23: Line Extensions for Brilinta/Brilique
Exhibit 24: Global Revenue of Brilinta/Brilique by AstraZeneca 2011-2013 (US$ million)
Exhibit 25: Global Revenue of Plavix by Bristol-Myers Squibb 2010-2012 (US$ million)
Exhibit 26: Revenue of Eli Lilly by Therapeutic Area 2013
Exhibit 27: Global Revenue of Effient by Eli Lilly 2010-2013 (US$ million)
Exhibit 28: Global Revenue of Arixtra by GlaxoSmithKline 2011-2013 (US$ million)
Exhibit 29: Global Revenue of Plavix by Sanofi 2011-2013 (US$ million)
Exhibit 30: Global Revenue of Lovenox by Sanofi 2011-2013 (US$ million)
Exhibit 31: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 32: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 33: AstraZeneca: Revenue by Geography 2013
Exhibit 34: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 35: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 36: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 37: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 38: Eli Lilly: Revenue by Geography 2013
Exhibit 39: GlaxoSmithKline: Business Segmentation 2013
Exhibit 40: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 41: GlaxoSmithKline: Revenue by Geography 2013
Exhibit 42: GlaxoSmithKline: Pipeline Products 2013
Exhibit 43: Sanofi: Business Segmentation
Exhibit 44: Sanofi: Revenue by Business Segmentation 2013
Exhibit 45: Sanofi: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 46: Sanofi: Revenue by Geographical Segmentation 2013
